ME01757B - 5-(2-{[6-(2 , 2-difluor0-2-feniletoksi )heksil]amin0}-1-hidroksietil)-8-hidroksiki nolin-2-(1 h)-on za lečenje plućne funkcije - Google Patents

5-(2-{[6-(2 , 2-difluor0-2-feniletoksi )heksil]amin0}-1-hidroksietil)-8-hidroksiki nolin-2-(1 h)-on za lečenje plućne funkcije

Info

Publication number
ME01757B
ME01757B MEP-2013-117A MEP11713A ME01757B ME 01757 B ME01757 B ME 01757B ME P11713 A MEP11713 A ME P11713A ME 01757 B ME01757 B ME 01757B
Authority
ME
Montenegro
Prior art keywords
hydroxyquinolin
phenylethoxy
difluoro
hexyl
hydroxyethyl
Prior art date
Application number
MEP-2013-117A
Other languages
English (en)
Inventor
Thorsten Ruf
Montejo Eric Massana
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of ME01757B publication Critical patent/ME01757B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
MEP-2013-117A 2009-02-18 2010-02-18 5-(2-{[6-(2 , 2-difluor0-2-feniletoksi )heksil]amin0}-1-hidroksietil)-8-hidroksiki nolin-2-(1 h)-on za lečenje plućne funkcije ME01757B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382020A EP2221055A1 (en) 2009-02-18 2009-02-18 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function
PCT/EP2010/001026 WO2010094483A1 (en) 2009-02-18 2010-02-18 5- (2-{ [6- (2, 2-difluoro-2-phenylethoxy) hexyl] amino} -1-hydroxyethyl) -8-hydroxyquinolin-2 (ih)-one for the treatment of lung function
EP10711830.9A EP2398473B1 (en) 2009-02-18 2010-02-18 5-(2-{[6-(2, 2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2-(1H)-one for the treatment of lung function

Publications (1)

Publication Number Publication Date
ME01757B true ME01757B (me) 2014-09-20

Family

ID=40833525

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2013-117A ME01757B (me) 2009-02-18 2010-02-18 5-(2-{[6-(2 , 2-difluor0-2-feniletoksi )heksil]amin0}-1-hidroksietil)-8-hidroksiki nolin-2-(1 h)-on za lečenje plućne funkcije

Country Status (33)

Country Link
US (2) US20120029014A1 (me)
EP (2) EP2221055A1 (me)
JP (1) JP2012518019A (me)
KR (1) KR20110123742A (me)
CN (2) CN102325530A (me)
AR (1) AR075432A1 (me)
AU (1) AU2010214854A1 (me)
CA (1) CA2749059C (me)
CL (1) CL2011002001A1 (me)
CO (1) CO6361939A2 (me)
CY (1) CY1114484T1 (me)
DK (1) DK2398473T3 (me)
EA (1) EA022442B1 (me)
EC (1) ECSP11011336A (me)
ES (1) ES2430596T3 (me)
HK (1) HK1159990A1 (me)
HR (1) HRP20130917T1 (me)
IL (1) IL213979A0 (me)
ME (1) ME01757B (me)
MX (1) MX2011008577A (me)
MY (1) MY155657A (me)
NZ (1) NZ593727A (me)
PE (1) PE20120419A1 (me)
PL (1) PL2398473T3 (me)
PT (1) PT2398473E (me)
RS (1) RS52951B (me)
SG (2) SG2014012827A (me)
SI (1) SI2398473T1 (me)
TW (2) TW201031408A (me)
UA (1) UA103370C2 (me)
UY (1) UY32414A (me)
WO (1) WO2010094483A1 (me)
ZA (1) ZA201104654B (me)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2668941A1 (en) * 2012-05-31 2013-12-04 Almirall, S.A. Novel dosage form and formulation of abediterol

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688V0 (it) 1979-02-05 1979-02-05 Chiesi Paolo Parma Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore.
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
DE69132850T2 (de) 1990-09-26 2002-05-29 Pharmachemie B.V., Haarlem Wirbelkammer-Pulverinhalator
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
AU683036B2 (en) 1992-12-18 1997-10-30 Merck Sharp & Dohme Corp. Inhaler for powdered medications
ES2206572T3 (es) 1995-04-14 2004-05-16 Smithkline Beecham Corporation Inhalador de dosis medida para salmeterol.
PL182198B1 (en) 1995-06-21 2001-11-30 Asta Medica Ag Pharmaceutic powder holding container with integrated measuring device and powdered
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
FR2903168B1 (fr) * 2006-06-30 2008-08-22 Fayard Eliane Bruleur pour realiser la combustion de substances reputees difficilement combustibles
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
UY32297A (es) * 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico

Also Published As

Publication number Publication date
CO6361939A2 (es) 2012-01-20
ES2430596T3 (es) 2013-11-21
TW201031408A (en) 2010-09-01
WO2010094483A1 (en) 2010-08-26
TW201442711A (zh) 2014-11-16
MX2011008577A (es) 2011-09-06
EA022442B1 (ru) 2016-01-29
EP2398473A1 (en) 2011-12-28
CA2749059A1 (en) 2010-08-26
EP2221055A1 (en) 2010-08-25
ZA201104654B (en) 2012-02-29
PT2398473E (pt) 2013-09-30
UA103370C2 (uk) 2013-10-10
PL2398473T3 (pl) 2013-12-31
DK2398473T3 (da) 2013-10-21
EP2398473B1 (en) 2013-07-24
CL2011002001A1 (es) 2011-11-11
SI2398473T1 (sl) 2013-11-29
IL213979A0 (en) 2011-08-31
JP2012518019A (ja) 2012-08-09
HK1159990A1 (en) 2012-08-10
CN105326838A (zh) 2016-02-17
AR075432A1 (es) 2011-03-30
EA201101210A1 (ru) 2012-03-30
CA2749059C (en) 2017-08-01
KR20110123742A (ko) 2011-11-15
AU2010214854A1 (en) 2011-07-21
SG2014012827A (en) 2014-04-28
NZ593727A (en) 2013-07-26
ECSP11011336A (es) 2011-10-31
US20120029014A1 (en) 2012-02-02
PE20120419A1 (es) 2012-05-09
CN102325530A (zh) 2012-01-18
UY32414A (es) 2010-07-30
RS52951B (en) 2014-02-28
HRP20130917T1 (hr) 2013-11-08
CY1114484T1 (el) 2016-10-05
US20140343097A1 (en) 2014-11-20
SG173091A1 (en) 2011-08-29
MY155657A (en) 2015-11-13

Similar Documents

Publication Publication Date Title
IL213979A0 (en) 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2 (1h)-one for the treatment of lung function
ZA201103312B (en) Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one as agonist of the b2 adrenergic receptor
HK1133011A1 (en) Napadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1- hydroxyethyl)-8-hydroxyquinolin-2(1h)-one as agonist of the beta 2 adrenergic receptor
SMT201300019B (it) Procedimento per la fabbricazione di 5-(2-{[6-(2,2-difluoro-2-feniletossi)esil]ammino]}-1-idrossietil)-8-idrossichinolin-2(1H)-one
HK1163081A1 (en) 6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof 6- 3-
IL215517A0 (en) 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines
IL213980A0 (en) 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-l-hydroxyethyl)-8-hydroxyquinolin-2 (1h)-one and its use in the treatment of pulmonary diseases
IL215483A0 (en) Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
ZA201405480B (en) Novel polymorphic crystal forms of 5-(2-{[6-(2,2-diflouro-2-phenylethoxy)hexyl]amino}-1-(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the beta2 adrenergic receptor
EP2269994A4 (en) POLYMORPHES OF 4-ANILINOCHINAZOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USES
IL196602A0 (en) Processes for the preparation of montelukast
EP2069307A4 (en) PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS
IL231284A0 (en) Process for preparing, 5 – (2 – {[6 – (2,2 – difluoro – 2 – phenylethoxy)hexyl] amino} – 1 (r) – hydroxyethyl) – 8 – hydroxyquinoline – 2 (1h) – one by an intermediate compound new